CSJ117A
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $648,719 | 47 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $648,719 | 47 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. | Novartis Pharmaceuticals Corporation | $621,664 | 0 |
| A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. | NOVARTIS PHARMACEUTICALS CORPORATION | $27,055 | 0 |
Top Doctors Receiving Payments for CSJ117A
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Birmingham, AL | $648,719 | 47 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $621,664
- NOVARTIS PHARMACEUTICALS CORPORATION $27,055
Product Information
- Type Drug
- Total Payments $648,719
- Total Doctors 0
- Transactions 47
About CSJ117A
CSJ117A is a drug associated with $648,719 in payments to 0 healthcare providers, recorded across 47 transactions in the CMS Open Payments database. The primary manufacturer is NOVARTIS PHARMACEUTICALS CORPORATION.
Payment data is available from 2020 to 2020. In 2020, $648,719 was paid across 47 transactions to 0 doctors.
The most common payment nature for CSJ117A is "Unspecified" ($648,719, 100.0% of total).
CSJ117A is associated with 2 research studies, including "A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA." ($621,664).